|
Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Says resolutions put forward at general meeting, including name change, share consolidation and cancellation of AIM listing, approved. Under the consolidation, every 20 shares will be consolidated into one new ordinary share. Adds that ratio of American depositary shares will change to one ADS per five shares, from one ADS per 25 shares previously. Name change to Biodexa Pharmaceuticals PLC, effective on Monday, also approved. Listing of shares on AIM is expected to be cancelled a month from now. Its sole listing will be on Nasdaq. Current stock price: 0.99 pence 12-month change: down 92% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
